Literature DB >> 18951300

Ocrelizumab, a humanized monoclonal antibody against CD20 for inflammatory disorders and B-cell malignancies.

Gabor Hutas1.   

Abstract

Biogen Idec Inc, Genentech Inc, Roche Holding AG and Chugai Pharmaceutical Co Ltd are developing ocrelizumab, a humanized mAb against CD20, for the potential treatment of inflammatory disorders and B-cell malignancies. Ocrelizumab is undergoing phase III clinical trials for rheumatoid arthritis and lupus nephritis, and phase II trials for multiple sclerosis and hematological cancer. Previously, ocrelizumab was also being developed for the treatment of systemic lupus erythematosus (SLE) and neuromyelitis optica; however, development for SLE has been discontinued. No development has been reported for neuromyelitis optica and as of January 2007, this indication had been removed from the company pipeline.

Entities:  

Mesh：

Substances：

Year:  2008        PMID： 18951300

Source DB:  PubMed          Journal:  Curr Opin Investig Drugs        ISSN： 1472-4472


  13 in total

1.  7th annual European Antibody Congress 2011: November 29-December 1, 2011, Geneva, Switzerland.

Authors:  Alexey A Lugovskoy; Janice M Reichert; Alain Beck
Journal:  MAbs       Date:  2012-03-01       Impact factor: 5.857

Review 2.  Recent Advances in Monoclonal Antibody Therapies for Multiple Sclerosis.

Authors:  Bharath Wootla; Jens O Watzlawik; Nikolaos Stavropoulos; Nathan J Wittenberg; Harika Dasari; Murtada A Abdelrahim; John R Henley; Sang-Hyun Oh; Arthur E Warrington; Moses Rodriguez
Journal:  Expert Opin Biol Ther       Date:  2016-03-10       Impact factor: 4.388

Review 3.  Evolution of anti-CD20 monoclonal antibody therapeutics in oncology.

Authors:  Ezogelin Oflazoglu; Laurent P Audoly
Journal:  MAbs       Date:  2010-01-30       Impact factor: 5.857

Review 4.  Targeting B cells with biologics in systemic lupus erythematosus.

Authors:  Antonio La Cava
Journal:  Expert Opin Biol Ther       Date:  2010-10-04       Impact factor: 4.388

Review 5.  Monoclonal antibody therapy in multiple sclerosis: Paradigm shifts and emerging challenges.

Authors:  Paulo Fontoura
Journal:  MAbs       Date:  2010 Nov-Dec       Impact factor: 5.857

Review 6.  Treatment of systemic lupus erythematosus with epratuzumab.

Authors:  Pawel Traczewski; Lidia Rudnicka
Journal:  Br J Clin Pharmacol       Date:  2011-02       Impact factor: 4.335

Review 7.  Monoclonal antibody therapy with rituximab for acute lymphoblastic leukemia.

Authors:  Deborah A Thomas; Susan O'Brien; Hagop M Kantarjian
Journal:  Hematol Oncol Clin North Am       Date:  2009-10       Impact factor: 3.722

8.  Risk-benefit considerations in the treatment of relapsing-remitting multiple sclerosis.

Authors:  Alessandra Lugaresi; Maria di Ioia; Daniela Travaglini; Erika Pietrolongo; Eugenio Pucci; Marco Onofrj
Journal:  Neuropsychiatr Dis Treat       Date:  2013-06-24       Impact factor: 2.570

Review 9.  Molecular pathogenesis of neuromyelitis optica.

Authors:  Wajih Bukhari; Michael H Barnett; Kerri Prain; Simon A Broadley
Journal:  Int J Mol Sci       Date:  2012-10-11       Impact factor: 5.923

Review 10.  Emerging New Approaches in Desensitization: Targeted Therapies for HLA Sensitization.

Authors:  Ashley Y Choi; Miriam Manook; Danae Olaso; Brian Ezekian; Jaeberm Park; Kyle Freischlag; Annette Jackson; Stuart Knechtle; Jean Kwun
Journal:  Front Immunol       Date:  2021-06-11       Impact factor: 7.561
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.